Martinelli G.; Soverini S.; Iacobucci I., What we don’t know about resistance to tyrosine kinase inhibitors in CML: what makes CML cells a tougher enemy than expected?, «CLINICAL LEUKEMIA», 2008, 2, pp. 86 - 87 [Scientific article]
Bussolari R; Candini O; Colomer D; Corradini F; Guerzoni C; Mariani SA; Cattelani S; Silvestri C; Pecorari L; Iacobucci I; Soverini S; Fasano T; Martinelli G; Cervantes F; Calabretta B., Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients, «LEUKEMIA RESEARCH», 2007, 31, pp. 163 - 167 [Scientific article]
Rosti, Gianantonio; Iacobucci, Ilaria; Bassi, Simona; Castagnetti, Fausto; Amabile, Marilina; Cilloni, D; Poerio, A; Soverini, Simona; Palandri, Francesca; Rege Cambrin, G; Iuliano, F; Alimena, G; Latagliata, R; Testoni, Nicoletta; Pane, F; Saglio, G; Baccarani, Michele; Martinelli, Giovanni, Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party., «HAEMATOLOGICA», 2007, 92, pp. 101 - 105 [Scientific article]
Iacobucci I; Galletti L; Amabile M; Soverini S; Baccarani M; Martinelli G., Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio, «HAEMATOLOGICA», 2007, 92, pp. 429 - 430 [Scientific article]
Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M., Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance, «BIOLOGICS», 2007, 1, pp. 121 - 127 [Scientific article]Open Access
Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain, «HAEMATOLOGICA», 2007, 92, pp. 401 - 404 [Scientific article]
Soverini S.; Baccarani M.; Iacobucci I.; Martinelli G., Resistance to tyrosine kinase inhibitors in Philadelphia chromosome-positive leukemias: which mutations matter?, «CLINICAL LEUKEMIA», 2007, 1, pp. 223 - 228 [Scientific article]
Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M., Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL, «THE LANCET ONCOLOGY», 2007, 8, pp. 273 - 274 [Scientific article]
Soverini S; Iacobucci I; Baccarani M; Martinelli G., Targeted therapy and the T315I mutation in Philadelphia-positive leukemias., «HAEMATOLOGICA», 2007, 92, pp. 437 - 439 [Scientific article]
Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G., The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study., «HAEMATOLOGICA», 2007, 92, pp. 1173 - 1179 [Scientific article]
Iacobucci, I.; Lonetti, A.; Ottaviani, E.; Cilloni, D.; Messa, F.; Paolini, S.; Papayannidis, C.; Panagiota, G.; Soverini, S.; Amabile, M.; Poerio, A.; Rondoni, M.; Saglio, G.; Pane, F.; Berton, G.; Baruzzi, A.; Vitale, A.; Foà, R.; Baccarani, M.; Martinelli, G., The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors., in: Volume 110, Issue 11, «BLOOD», 2007, Volume 110, pp. 722 - 722 (atti di: 49th Annual Meeting of the American Society of Hematology (ASH)., Atlanta., December 8-11, 2007) [Abstract]
Cilloni D; Messa F; Martinelli G; Gottardi E; Arruga F; Defilippi I; Carturan S; Messa E; Fava M; Giugliano E; Rosso V; Catalano R; Merante S; Nicoli P; Rondoni M; Ottaviani E; Soverini S; Tiribelli M; Pane F; Baccarani M; Saglio G., WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia., «LEUKEMIA», 2007, 21, pp. 1442 - 1450 [Scientific article]
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G, Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients., «CLINICAL CANCER RESEARCH», 2006, 12, pp. 3037 - 3042 [Scientific article]
Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G., Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies, in: , «HAEMATOLOGICA», 2006, 91(s3), pp. 31 - 31 (atti di: IX congresso della Società Italiana di Ematologia Sperimentale (SIES)., Napoli, Italy, 20-22/09/2006) [Abstract]
IACOBUCCI I; ROSTI G; AMABILE M; POERIO A; SOVERINI S; CILLONI D; TESTONI N; ABRUZZESE E; MONTEFUSCO E; OTTAVIANI E; IULIANO F; RUSSO D; GOBBI M; ALIMENA G; MARTINO B; TERRAGNA C; PANE F; SAGLIO G; BACCARANI M; MARTINELLI G, Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment., «JOURNAL OF CLINICAL ONCOLOGY», 2006, 24, pp. 454 - 459 [Scientific article]
